- Vaccine Name: Menveo
- Target Pathogen: Neisseria meningitidis
- Target Disease: Meningitis
- Product Name: Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine
- Tradename: Menveo
- Manufacturer: Novartis Vaccines and Diagnostics, Inc.
- Vaccine Ontology ID: VO_0001246
- CDC CVX code: 136
- Type: Conjugate vaccine
- Status: Licensed
- Location Licensed: USA, Canada
- Host Species for Licensed Use: Human
- Antigen: N. meningitidis serogroup A, C, Y and W-135 oligosaccharides conjugated individually to Corynebacterium diphtheriae CRM197 protein (FDA: Menveo).
- Preparation: The polysaccharides are produced by bacterial fermentation of N. meningitidis (serogroups A, C, Y or W-135). N. meningitidis strains A, C, Y and W-135 are each cultured and grown on Franz Complete medium and treated with formaldehyde. MenA, MenW-135 and MenY polysaccharides are purified by several extraction and precipitation steps. MenC polysaccharide is purified by a combination of chromatography and precipitation steps. The protein carrier (CRM197) is produced by bacterial fermentation and is purified by a series of chromatography and ultrafiltration steps. C. diphtheriae is cultured and grown on CY medium containing yeast extracts and amino acids. The oligosaccharides are prepared for conjugation from purified polysaccharides by hydrolysis, sizing, and reductive amination. After activation, each oligosaccharide is covalently linked to the CRM197 protein. The resulting glycoconjugates are purified to yield the four drug substances, which compose the final vaccine (FDA: Menveo).
- Immunization Route: Intramuscular injection (i.m.)
- Storage: Store refrigerated, away from the freezer compartment, at 36°F to 46°F (2°C to 8°C). Keep away from light (FDA: Menveo).
- Approved Age for Licensed Use: MENVEO is approved for use in persons 11 to 55 years of age (FDA: Menveo).
- Description: MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine] is a sterile liquid vaccine administered by intramuscular injection that contains N. meningitidis serogroup A, C, Y and W-135 oligosaccharides conjugated individually to Corynebacterium diphtheriae CRM197 protein (FDA: Menveo).
|
